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Abstract
Preferentially delivering ionizing radiation to target tissues during radiotherapy pro-
cedures is investigated using internal radiation-generating devices and microspheres 
loaded with radioactive material. This chapter presumes the existence of internal 
 radiation-generating devices and develops their requisite characteristics to permit the 
selective irradiation of tumors. The feasibility of disrupting a tumor’s vascular structure 
is also investigated. Calculated absorbed dose profiles for both approaches demonstrate 
that dose can be successfully localized in a target tissue while minimizing the delivery 
to healthy tissue.
Keywords: absorbed dose, internal radiation-generating devices, microspheres, 
radiation therapy, tumor vascular disruption
1. Introduction
A significant issue associated with existing radiotherapy approaches is that agents that 
deliver dose to tumor cells also irradiate healthy tissue [1–6]. Short-term as well as long-term 
detriments can appear following radiotherapy procedures. These effects occur when healthy 
tissue outside the target volume is irradiated and affect the patient’s subsequent recovery 
and quality of life. For example, short-term detriments (e.g., incontinence and erectile dys-
function) occur following prostate cancer therapy [7]. Long-term effects include second-
ary cancers and cardiovascular disease [8]. In view of these detriments, alternative therapy 
approaches that preferentially deliver dose to the target tissue are of interest and should be 
investigated.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
This chapter considers two approaches that have the potential to significantly minimize the 
dose to healthy tissue while maximizing the dose delivered to the target tissue. The first tech-
nique utilizes internal radiation-generating devices that are in their conceptual development 
phase, and the second is an enhancement of the 90Y microsphere approach that has been suc-
cessfully utilized to treat liver cancers by disrupting the tumor’s vasculature.
Heavy ions, neutrons, protons, and other radiation types have numerous applications 
for treating a variety of cancers [1–3, 6, 9–14]. To date, these techniques have focused on 
beams originating outside the body. These external beams selectively irradiate the tumor 
mass, but still deliver some dose to healthy tissue. This chapter investigates the possibility 
of using radiation-generating devices that would be implanted within a tumor to pref-
erentially irradiate its volume and develops their requisite characteristics to permit the 
selective irradiation of tumors. These devices are postulated to have a size on the order 
of 10−6 m [1–3, 6].
Microspheres offer a unique approach that has the potential to impact tumor cells by disrupt-
ing their vascular structure. A number of authors [15, 16] have proposed a therapy approach 
that prevents the development of the tumor’s vascular supply. Vascular disruption agents 
incorporate both chemotherapy [17, 18] as well as radiotherapy [18–27]. Radiotherapy vascu-
lar disruption techniques utilizing 90Y microspheres, including anti-angiogenic and radioem-
bolization therapies, are used to treat liver cancers [18–23]. Other radionuclides (e.g., 32P) are 
under investigation, but radiation types other than high-energy beta particles are not under 
active consideration [22].
2. Internal radiation-generating devices
The requisite technology to construct internal radiation-generating devices (IRGDs) is being 
developed (e.g., electron accelerators powered by lasers [28]). These devices are optical 
 cavities [28] whose size depends on the laser’s wavelength. The utilization of shorter wave-
length lasers leads to devices of the size envisioned for IRGDs [1–3, 6].
Refs. [1–6] provide calculations for the range of heavy ions in water. By selecting appropriate 
ion and energy combinations, specific target irradiation locations are preferentially irradi-
ated. The capability to localize dose in the target is a positive feature that makes heavy ions 
an attractive tool for external beam therapy and supports their potential use in an IRGD. By 
adjusting the beam energy and radiation type, an IRGD has the capability to selectively irradi-
ate the tumor.
2.1. Candidate radiation types
Internal devices could incorporate pions, muons, photons, electrons, protons, and heavy ions to 
deposit energy into tumors. Ranges on the order of a centimeter are achieved using 10–20 MeV 
pions and muons, 30–40 MeV protons, 100–200 MeV alpha particles, and energies on the order 
of 90 MeV/nucleon for 12C, 16O, 20Ne ions, and heavier ions [1–6].
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2.2. IRGD characteristics and arrangement
The feasibility of using IRGDs for therapy applications is illustrated using a cubic Cartesian 
configuration. This configuration is repeated to irradiate various tumor sizes. A unit cell con-
cept is arbitrary, but simplifies the calculation of absorbed dose to the tumor site.
The cubic Cartesian configuration utilizes 27 devices arranged in three planes with nine devices 
in each plane. The coordinates of the devices are written in terms of a scaled  dimension ξ:
  ξ =  R __
d
(1)
where d is the internal device grid spacing and R is the maximum ion range. This approach facil-
itates a general discussion and eliminates adjustments for specific ion-energy combinations.
The 27 devices reside at the locations (x, y, z): (0, 0, z), (ξ, 0, z), (ξ, − ξ, z), (0 − ξ, z), (−ξ, − ξ, z), 
(−ξ, 0, z), (−ξ, ξ, z), (0, ξ, z), and (ξ, ξ, z) for z = -ξ, 0, and ξ. Utilizing additional devices 
enhances the delivery of dose in a more uniform manner.
IRGDs should incorporate a number of characteristics to facilitate the dose delivery to the 
target volume. In general, the IRGDs should have the capability to (1) irradiate 4π steradians, 
(2) deliver various ion-energy combinations, (3) be controlled in real time, (4) rapidly change 
the radiation type, energy, and fluence, (5) produce a variable fluence to deliver a uniform 
dose, (6) position itself at a desired location, (7) monitor the delivered dose profile using posi-
tron emission tomography or other techniques to verify that it is preferentially irradiating the 
tumor volume, and (8) have the capability to be removed from the body.
Delivering a uniform absorbed dose (D) requires careful control of the fluence, ion type, and 
energy (E). These parameters are varied during the irradiation time (T) to deliver a uniform 
dose within the unit cell:
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fluence rate, N is the number of implanted devices, and i labels the individual device [1–3, 6].
2.3. Absorbed dose calculations
Eq. (2) is used to calculate the absorbed dose from internal radiation-generating devices 
within a Cartesian lattice. Stopping powers are determined using the methodology outlined 
in Refs. [1–6], and energy-dependent cross sections are obtained from Shen et al’s parameter-
ization [29] or models [1–6].
As an initial example of the internal device concept, a spectrum of eight proton groups 
(i.e., 10, 20, 30, 40, 50, 60, 70, and 80 MeV) is selected to be the output of the device. A  spectrum 
of energies facilitates the irradiation of the entire tumor volume. A uniform distribution of 
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 proton dose requires a continuous proton energy distribution. The 27 proton generating 
devices are distributed in a 10 × 10 × 10 cm volume of water. Each device is assumed to radi-
ate isotropically. The results of irradiating this water volume with 27 internal devices gen-
erating an output of 10, 20, 30, 40, 50, 60, 70, and 80 MeV protons are illustrated in Figure 1. 
The  fluence at each proton energy is selected to be the same.
Since the total absorbed dose of Figure 1 is the superposition of a number of manifolds (i.e., 
the various isodose surfaces), the structure of the surface is governed by the proton output 
spectrum, fluence, attenuating medium characteristics, ion stopping power, and reaction 
cross section as noted in Eqs. (1) and (2). Figure 1 represents the three-dimensional absorbed 
dose profile. In Figure 1, the dose at each point is proportional to the plotted circle radius.
Figure 1 illustrates the symmetry of the absorbed dose distribution associated with the 27 inter-
nal radiators. Although the distribution is not uniform, the IRGDs effectively irradiate the tar-
get volume. The average dose to the target 10 × 10 × 10 cm volume depends on the IRGD proton 
spectrum. For example, proton energy groups of 10 MeV; 10 and 20 MeV; 10, 20, 30, and 40 
MeV; and 10, 20, 30, 40, 50, 60, 70, and 80 MeV produce to an average dose over the target vol-
ume of 5.89 × 10−6, 5.75 × 10−4, 3.00 × 10−2, and 9.79 × 10−2 relative to the peak dose, respectively.
Increasing the number of proton energy groups between 10 and 80 MeV range will continue 
to increase the average absorbed dose to the tumor site. The discussion of the characteristics 
of the detailed three-dimensional absorbed dose profile illustrates the complexity of therapy 
planning when implementing a new technology.
Figure 1. Normalized absorbed dose distribution from 27 internal radiation-generating devices producing a spectrum of 
eight proton groups (i.e., 10, 20, 30, 40, 50, 60, 70, and 80 MeV protons). The absorbed dose is proportional to the plotted 
circle radius.
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3. Radionuclide vascular disruption therapy using microspheres
Conventional radiotherapy often involves the deposition of the radionuclide within a tumor 
mass. It is also feasible to attack the tumor by disrupting its blood supply. Vascular disruption 
agents have been developed and utilized in chemotherapy and radiotherapy.
3.1. Tumor vasculature
The vascular structure of normal tissue provides an efficient method to deliver nutrients. 
Growing tumors have a poorly developed vasculature that does not adequately nourish 
the cells [17]. The tumor’s weak vascular structure can be degraded using a chemical or 
radioactive agent.
Vessels that are dilated and have elongated shapes, blind ends, bulges, leaky sprouts, and 
abrupt diameter changes are defects that occur in a tumor’s vascular structure. These vessel 
defects create sluggish and irregular blood flow that poorly nourish cancer cells and result in 
hypoxic tumors. Hypoxic conditions limit the effectiveness of both chemotherapy and radio-
therapy and provide a measure of radioresistance to tumor cells when compared to normal, 
oxygenated cells. Since a tumor’s growth is dependent on sufficient nourishment, eliminating 
its blood supply provides an additional opportunity to facilitate its destruction [17].
3.2. Current radiological efforts
Radiological efforts at tumor vascular disruption have focused on 90Y. 90Y was a logical choice 
for anti-angiogenic therapy since the dose to destroy a tumor is ≥70 Gy. However, the 2.27 
MeV 90Y beta particles have a range in tissue of about 1.1 cm, which deposits dose to healthy 
tissue well beyond the target vasculature. Bremsstrahlung from the 90Y beta particles provides 
additional dose to healthy tissue. The properties of 90Y microspheres used in therapy applica-
tions are summarized by Kennedy et al. [22].
Medical reviews suggest that the 90Y approach is a safe and effective therapy method for 
selected patients. However, a number of negative features are associated with 90Y microsphere 
therapy [22]. First, 90Y bremsstrahlung affects healthy tissue well beyond the vasculature. 
Second, resin microspheres may have trace 90Y on their surface, which is excreted through 
urine. As the 90Y is excreted, additional absorbed dose is delivered to healthy tissues. Third, 
the total dose delivered to the lung should not exceed 30 Gy to prevent radiation pneumonitis. 
Fourth, patients can exhibit abdominal pain, fatigue, and nausea within three days posttreat-
ment. Fifth, dose delivered to healthy tissue causes acute damage that includes pancreatitis, 
gastrointestinal ulceration, and radiation pneumonitis. Radiation-induced liver disease is a 
possible late effect of 90Y microsphere therapy.
3.3. Theoretical methodology
A tumor’s blood supply is reduced by a vascular disruption agent that causes the vessel wall 
to become restricted or breached to increase leakage. IRGDs and microspheres using alpha-
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emitting radionuclides (MAs) preferentially deliver absorbed dose to the blood vessel wall to 
facilitate its disruption. The wall thicknesses for a variety of human blood vessel types [30] 
are summarized in Table 1.
Tumor vessel wall sizes, including arterioles, are usually <100 μm [17]. Although arterioles 
are used as the base case in this chapter, the vessel sizes summarized in Table 1 suggest that 
a variety of blood vessel types could service a developing tumor [30].
3.4. Microsphere radionuclide selection and characteristics
An alternative to the use of 90Y is provided by radionuclides that emit low-energy photons, 
low-energy beta particles, or alpha particles. These radionuclides would replace 90Y as the 
radioactive material loading the microspheres.
Desirable characteristics for the radionuclide and candidate microsphere to facilitate tumor 
blood vessel disruption include the (1) nuclide has a short effective half-life, (2) range of the 
emitted radiation is <100 μm or the maximum vessel wall thickness, (3) arteriole wall dose is 
at least 100 Gy, (4) healthy tissue dose is minimized, (5) microsphere preferentially attaches 
to the wall of the tumor’s arteriole, (6) candidate radionuclide is compatible with the micro-
sphere, and (7) the microsphere can be removed from the body at a desired time.
Although these characteristics provide a basis for the calculations presented in this chapter, 
they have not been optimized to produce a viable alternative to the 90Y microsphere approach. 
As noted in Refs. [4–6], both alpha-emitting and low-energy beta-gamma loaded microspheres 
can be utilized to disrupt a tumor’s vasculature. However, the daughter radiation presents a 
problem, and this radiation can often irradiate healthy tissue that was an original concern 
associated with the 90Y approach.
Production challenges and associated availability are impediments for the use of alpha-emit-
ting radionuclides. Therefore, the availability of the selected radionuclide is an important 
Blood vessel type Wall thickness Lumen diameter
Aorta 2 mm 25 mm
Artery 1 mm 4 mm
Arteriole 20 μm 30 μm
Capillary 1 μm 8 μm
Venule 2 μm 20 μm
Vein 0.5 mm 5 mm
Vena Cava 1.5 mm 30 mm
aBarrett et al. [30].
Table 1. Characteristics of various blood vessel typesa.
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consideration. 222Rn is readily available and would be a candidate for microsphere use. The 
222Rn daughters yield additional dose to the tumor vasculature, which could enhance the 
approach if healthy dose is avoided.
3.4.1. Selection of radionuclide
In Refs. [4–6], a list of candidate alpha- and beta-gamma-emitting radionuclides was created. 
Unfortunately, most candidate radionuclides, including 149Tb, 211At, 212Bi, 213Bi, 223Ra, 225Ac, and 
227Th, have daughter gamma, beta, or bremsstrahlung radiation that irradiates healthy tis-
sue well beyond the target volume, which does not meet the goal of minimizing the dose 
delivered beyond the arteriole wall. As part of that goal, 222Rn was noted as an interesting 
possibility since it occurs naturally as part of the 238U decay chain. Eq. (3) lists the 222Rn decay 
daughters with the associated decay scheme:
  
 222 R  n  α   ⟶  218 P  o     α   ⟶    214 P  b   
β − 
   ⟶  214 B  i  
 
  
 β − 
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α
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  (3)
Although 222Rn has a number of desirable characteristics, its daughters emit beta and 
gamma radiation that deliver absorbed dose well beyond the thickness of the arteriole wall. 
Therefore, 222Rn is not a primary candidate to achieve selective dose delivery to the vascular 
wall. However, a review of the 222Rn daughters suggests that 210Po has the desired characteris-
tics for vascular disruption without significantly irradiating healthy tissue. In particular, the 
210Po 5.3 MeV alpha particle irradiates the arteriole wall and limits the absorbed dose beyond 
the target tissue. In addition, the weak 803 keV 210Po photon radiation with a yield <1.0 × 10−3% 
delivers minimal dose beyond the target tissue.
3.4.2. Basic microsphere design
The base case microsphere is loaded with 0.3 Bq of 210Po uniformly distributed in a 1-μm-diameter 
12C sphere having a density of 2.0 g/cm3. Subsequent discussion provides the basis for the 0.3 
Bq activity.
Subsequent discussion is based on a single microsphere. However, treatment procedures 
will utilize many spheres with the actual number determined by the cancer type and 
its progression. Although microsphere delivery methods other than the usual catheter 
approach [2–6] may be feasible, initial efforts will likely focus on the traditional delivery 
method [17–23].
3.4.3. Absorbed dose computational model
A 210Po activity of 0.3 Bq delivers an absorbed dose of about 100 Gy to the arteriole wall. 
Defining a more exact activity value is not necessary because the design has yet to be refined. 
The activity value also depends on the insertion and removal methods, fabrication details, 
and relative biological effectiveness values for the 210Po alpha and gamma radiation.
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3.4.3.1. Absorbed dose from alpha particles
The absorbed dose (D) delivered by ions of a specific energy as a function of penetration dis-
tance x into tissue is [1, 12]:
  D ( x )  =   1 __ρ  ( −   dE _dx) Φ  ( x ) (4)
where ρ is the density of tissue attenuating the ion, −dE/dx is the stopping power, and Φ(x) 
is the alpha particle fluence at the location of interest. The particle fluence varies with tissue 
penetration depth according to the relationship:
  Φ ( x )  =  Φ ( 0 )  e −Σ x (5)
where Φ(0) is the entrance fluence and Σ is the macroscopic reaction cross section. Alpha 
particle stopping powers are derived from Bethe’s formulation [31] and follow an approach 
similar to the SPAR code [32]. The energy-dependent cross sections are obtained from Shen et 
al’s parameterization [29] or models [1–6].
3.4.3.2. Photon absorbed dose
The photon absorbed dose is derived from the standard point source relationships [4–6]:
  D  =   S ____ 
 4πr 2  
 μ 
en
 
 ___ρ E B ( μx )  e −μx (6)
where S is the total number of photons irradiating the arteriole wall, r is the distance from 
the microsphere, μ
en
/ρ is the mass-energy absorption coefficient, E is the photon energy, B is 
a buildup factor, and μ is the attenuation coefficient. The gamma absorbed dose contribution 
is obtained from the ISO-PC computer code [33]. Requisite photon data for 210Po are based on 
Rittman [33].
3.4.4. Relative biological effectiveness
In therapy applications, the absorbed dose is multiplied by the relative biological effective-
ness (RBE) to reflect the cell killing efficiency of a radiation type. The RBE of radiation type 
x is defined as the ratio of the dose of a reference energy photon to produce an effect and the 
dose of radiation type x to produce the same biological effect. Although the RBE is a simple 
concept, its therapy application is complex [34], because the RBE depends on a number of 
factors. These include the radiation type and its energy, the delivered absorbed dose, the 
delivery method (e.g., dose fractionization sequence), and the irradiated cell and tissue types. 
No RBE is applied to the absorbed doses calculated in this chapter because the design of the 
210Po microsphere is being developed. However, the alpha particle RBE is greater than unity. 
Therefore, the calculated absorbed doses for tumor disruption represent a lower bound for 
the dose delivered by the 210Po microsphere.
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3.4.5. Microsphere results and discussion
In subsequent discussion, the 210Po microsphere resides at the inner wall of an arteriole. Figures 2  
and 3 illustrate absorbed dose profiles for water thicknesses ≤100 μm. Following previous work, 
the vessel wall is assumed to be water that is a good approximation for tissue [1–6, 12].
Figure 2. Absorbed dose profile for 210Po alpha particles in a water medium. The absorbed dose is delivered by 0.3 Bq 
of 210Po uniformly deposited within a 1-μm-diameter microsphere following the total decay of the radioactive material.
Figure 3. Absorbed dose profile for 210Po photons in a water medium. The absorbed dose is delivered by 0.3 Bq of 
210Po uniformly deposited within a 1-μm-diameter microsphere following the total decay of the radioactive material.
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Figures 2 and 3 provide the results of alpha and gamma contributions to the absorbed dose 
from a 210Po microsphere, respectively. Since the gamma absorbed dose is significantly less than 
the alpha absorbed dose, Figure 2 represents the total absorbed dose delivered by the 210Po MA.
Since the peak dose is delivered at 35.9 μm, the 100 μm dose localization value is achieved. At 
the Bragg peak, the alpha to gamma dose ratio is 1.7 × 1010. Beyond the Bragg peak, 210Po pho-
tons deliver less than 0.1 μGy. Although 210Po MAs achieve the desired dose localization, its 
longer half life (138 d) relative to 32P (14.28 days) and 90Y (2.669 days) [35] must be addressed.
The time (t)-dependent dose rate to the arteriole wall is given by the relationship:
  D ˙ ( t )  =   D ˙ ( 0 )  e −λt (7)
where λ is the physical decay constant of the radionuclide. Integrating Eq. 7 yields the total 
dose at time T:
  D ( T )  =   
 D ˙ ( 0 ) 
 ____λ  ( 1 −   e −λT )  =  D ( ∞ )  ( 1 −  e −λT ) (8)
Since the activity is proportional to the delivered dose, early removal of the microsphere at 
time T requires an increase in the initial activity loading by a factor (F), which is the ratio of 
D(∞)/D(T) [5]:
  F  =   1 _________________ 
 ( 1 −  e −λT ) (9)
This activity increase delivers the required dose to disrupt the microsphere as noted in 
Figures 2 and 3. For example, an activity of about 2 Bq (0.3 Bq × 7.19) is the requisite 210Po 
activity loading to produce the doses summarized in Figures 2 and 3 if the microspheres are 
removed at 30 days (F(30 days) = 7.19).
3.4.6. Microsphere delivery methods
In initial studies, a catheter will introduce the MA into the tumor vasculature. Following the 
methodology developed in 90Y microsphere liver cancer therapy, the catheter enters through 
the femoral artery into the liver and deposits the microspheres into the tumor’s blood vessels. 
Image-guided radiation therapy [26, 36] facilitates guiding the catheter to specifically target 
the tumor vasculature.
The catheter delivery method could be utilized in the treatment of a number of tumors. 
Specific catheter paths for the various tumor types will be refined and developed in a man-
ner that was similar to the evolution of the 90Y microsphere treatment of liver cancers [17–23]. 
For example, renal artery access would facilitate 210Po MA deposition into the vasculature of 
kidney tumors.
Developing a method for preferentially depositing the MA into the desired blood vessel 
requires additional research and development. The microsphere research and design effort 
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should investigate a number of chemical and physical approaches. These approaches include 
the use of electric charge, heat, pH, and electromagnetic fields to achieve the desired attach-
ment of the MA to the tumor’s vascular wall. The specific design options that require experi-
mental effort include the MAs (1) electric charge and its spatial distribution, (2) dielectric 
and diamagnetic characteristics, (3) physical size and shape, and (4) material composition. 
Activating agents could be used to optimize the MA design. Electromagnetic fields heat, 
lasers, and a spectrum of electromagnetic radiation are possible activating agents.
3.4.7. Microsphere removal methods
Eqs. (7)–(9) suggest that extraction of MAs at a specified time requires the development of 
removal mechanisms. Removal could be accomplished by reversing the delivery methods 
discussed previously. For example, deposition and removal could be achieved by incorporat-
ing a magnetic material in the MA. The magnetic particles facilitate placement in the desired 
location using an active, localized magnetic field. Eliminating the magnetic field would facili-
tate microsphere removal. The protocol for microsphere implantation and removal requires 
additional research and development.
3.4.8. Effective half-life
As noted previously, the 210Po physical half-life (T
p
) must be addressed before the MA therapy 
application becomes a reality. The physical half-lives of 210Po and 90Y are 138 and 2.7 days, 
respectively. A 90Y delivery approach will not be successful for 210Po if the MA design does not 
shorten the biological half-life of the device.
In the case of the shorter half-life 90Y, some microspheres are transported via blood into the 
lung and irradiate healthy tissue. Since the physical half-life of 90Y is short, this deposition 
yields a relatively insignificant dose. Assuming the same transfer characteristics, 210Po pro-
duces a larger lung dose and could create a significant biological detriment. This concern is 
eliminated if the 210Po MA design produces a shorter biological half-life in the lung.
In view of these considerations, constructing 210Po MAs with a short effective half-life is a 
design requirement. For example, the 210Po MAs could be constructed using a material hav-
ing ICRP 30 [37] Class D lung retention characteristics. Following the ICRP 30 methodol-
ogy, Class D materials have a biological half-life <10 days. Part of 210Po MA development is 
the use of a material with a short biological half-life. The 210Po MA effective half-life in the 
lung is [38]:
  T 
e
  =   
 T 
p
   T 
b
 
 __________________________ 
 T 
p
  +   T 
b
 
(10)
Following Eq. (10), the effective half-life (T
e
) of a radionuclide depends on its biological and 
physical half-lives. Therefore, a long physical half-life is not a limiting factor if the biological 
half-life (T
b
) is short. For example, the 210Po effective half-life for a material with 2- and 10-day 
biological half-lives is 1.97 and 9.32 days, respectively. A MA design requirement for a Class 
D biological half-life eliminates the longer 210Po physical half-life concern.
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3.4.9. 210Po toxicity and patient safety
210Po has a specific activity of 1.7 × 1014 Bq/g, and its inhalation (ingestion) effective dose coef-
ficient (EDC) is 3.0 × 10−6 Sv/Bq (2.4 × 10−7 Sv/Bq) [39]. The intake pathway caused by MA 
leaching has not been evaluated. In view of the inhalation and ingestion EDCs, the leaching 
EDC is probably in the range of the established conventional intake pathway values. For an 
initial scooping assessment, the leaching EDC is approximately 10−6 Sv/Bq. Considering the 
proposed 0.3 Bq 210Po MA, complete 210Po leaching from a single microsphere produces to an 
effective dose of about 0.3 μSv.
The effective dose from complete MA leakage is mitigated if the microspheres have good 
retention characteristics. With good 210Po retention characteristics, the radiological hazard to 
the patient is not significant. For example, if 106 0.3 Bq MAs were administered with a 210Po 
retention of 90%, the patient’s 50-year effective dose commitment is only 30 mSv.
4. Vascular disruption using internal radiation-generating devices
Vascular disruption can also be achieved using internal radiation-generating devices. These 
devices meet the desired characteristics to maximize dose to the tumor’s vascular walls while 
minimizing the dose to healthy tissue. For a tissue volume irradiated by a beam of ions of a 
given energy, the absorbed dose (D) as a function of penetration distance into tissue is given 
by Eqs. (4) and (5). Arteriole vascular disruption is outlined for beams of protons, alpha par-
ticles, and 12C, 20Ne, and 40Ca ions. All beams were assumed to be fully ionized (e.g., 12C ions 
have a +6 e charge).
The photon absorbed dose is derived from Eq. (6). Because higher energy photons have poor 
dose localization, low-energy photons are investigated as a possible vascular disruption agent.
4.1. Internal radiation-generating device results and discussion
The base case considered in this chapter is the 20 μm arteriole wall thickness. With this 
emphasis, the dose delivered to the arteriole wall and blood vessel wall thicknesses ≤100 μm 
[17] is calculated. The target dose, which is about of 100 Gy, is sufficient to disrupt the vessel 
wall. Dose delivery has not been optimized, and ion fluences to reach the 100 Gy dose level 
are 5 × 109, 5 × 108, 1 × 108, 5 × 107, and 1 × 107 ions/cm2 for protons, alpha particles, 12C, 20Ne, 
and 40Ca, respectively. 1 × 1010 photons are utilized in the calculations using Eq. (6).
In subsequent absorbed dose calculations, the internal radiation-generating device is 
assumed to reside at the inner arteriole wall. Table 2 summarizes the calculations for photons, 
protons, alpha particles, and 12C, 20Ne, and 40Ca ions and compares these results with beta-
emitting nuclides currently used in therapy applications. To further illustrate the  internal 
 radiation-generating device concept, Figure 4 illustrates the 12C absorbed dose profiles for 
blood vessel wall depths ≤100 μm. The 12C energies included in Figure 4 are 10, 20, 25, 30, 40, 
and 50 MeV. Water is assumed to be the medium comprising the vessel wall.
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Radionuclide or radiation 
delivery approach
Radiation type emitted Range (μm) E (MeV)
90Y β− 1.1 × 104 2.281a
32P β− 7.9 × 103 1.709a
33P β− 5.9 × 102 0.249a
35S β− 3.2 × 102 0.1674a
IRGDb p 10–95 0.5–2.3
IRGDb α 15–75 3.0–8.0
IRGDb 12C 5–90 10.0–50.0
IRGDb 20Ne 10–85 30.0–110.0
IRGDb 40Ca 10–75 100.0–300.0
IRGDb γ 0–20c 0.015–0.050
IRGDb γ 0–70d 0.015–0.050
aMaximum beta energy.
bInternal radiation-generating device (IRGD).
cThe dose decreases by a factor of about 103 over the listed depths.
dThe dose decreases by a factor of about 104 over the listed depths.
Table 2. Dose localization for candidate radionuclides and radiation types.
Figure 4. Absorbed dose profiles for 12C ions in water. The absorbed dose curves peak at a greater depth with increasing 
12C ion energy. The total ion fluence for all energies is 1.0 × 108 12C ions/cm2. The ions are delivered by an internal 
radiation-generating device.
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Dose localization within an arteriole wall could be achieved using 1.0–1.5 MeV proton beams. 
Alpha particles with energies below 3 MeV will not penetrate the arteriole wall. The arteriole 
wall is disrupted, with minimal dose to surrounding tissue, by alpha particles in the 4–5 MeV 
energy range. Sufficient absorbed dose to disrupt vessels with wall thicknesses between 20 
and 100 μm can be delivered by alpha particles having energies below 8 MeV.
12C ions with energies below about 20 MeV do not penetrate the arteriole wall, and 20–50 
MeV ions will deposit sufficient energy into a range of vessel wall thicknesses in the 20–100 
μm range to produce vascular disruption. Selective arteriole wall disruption is achieved using 
25–30 MeV 12C ions. However, the generation of 12C, 20Ne, and 40Ca ions is a more significant 
technical challenge than producing lighter ions in a first generation IRGD.
20Ne ions below 30 MeV do not penetrate the arteriole wall. 20Ne ions in the range of 50–110 
MeV will be sufficient to reach the range of vessel wall thicknesses addressed in this chapter. 
Arteriole wall disruption with minimal dose to surrounding tissue is achieved using 50–70 MeV 
20Ne ions. In a similar manner, 40Ca ions require 150–200 MeV to selectively disrupt the arteriole 
wall and 100–300 MeV 40Ca ions penetrate vessel wall thicknesses of 10–75 μm.
Table 2 illustrates that photon energies in the range of 15–50 keV can deposit the requisite 
absorbed dose to disrupt an arteriole wall. Significant dose is also deposited in the 20–100 μm 
range by the 15–50 keV photons. However, protons and 4He, 12C, 20Ne, and 40Ca ions achieve 
better dose localization.
Internal radiation-generating devices can also be developed to emit low-energy electrons. 
Electrons present a concern because their bremsstrahlung radiation can irradiate healthy 
 tissue beyond the target volume. However, low-energy electrons preferentially irradiate the 
arteriole wall with minimal bremsstrahlung. Table 3 summarizes the range and bremsstrah-
lung production for 20–85 keV electrons impinging on the arteriole wall.
Electron energy (keV) Range in water (μm) Fraction of electron energy converted 
into bremsstrahlung
20 6.79 5.26 × 10−5
25 10.6 6.57 × 10−5
30 15.1 7.89 × 10−5
35 20.3 9.20 × 10−5
40 26.1 1.05 × 10−4
50 39.6 1.31 × 10−4
60 55.1 1.58 × 10−4
70 72.6 1.84 × 10−4
80 91.8 2.10 × 10−4
85 102 2.23 × 10−4
Table 3. Vascular disruption by low-energy electrons from an internal radiation-generating device.
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The results summarized in Table 3 suggest that 35–40 keV electrons also offer the potential to 
selectively disrupt an arteriole servicing a tumor. Dose localization is achieved with minimal 
bremsstrahlung production that permits vascular disruption without delivering absorbed 
dose to healthy tissue. Table 3 also illustrates that electrons below 85 keV also selectively 
irradiate vessel wall thicknesses below 100 μm.
5. Conclusions
Internal radiation-generating devices and microspheres loaded with alpha-emitting radionu-
clides preferentially deposit dose in the target tissues while minimizing the dose delivered to 
healthy tissue. This selective deposition minimizes stray dose and limits the side effects that 
often accompany radiotherapy procedures. The microsphere approach can be realized in the 
near term, but an internal radiation-generating device relies on technology that is not cur-
rently available. Additional research is required to develop the techniques proposed in this 
chapter into practical radiotherapy protocols.
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